Glaucoma and Ocular Hypertension

Cardiovascular
3
Pipeline Programs
1
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
1
0
0
2
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

S
SantenCA - Emeryville
3 programs
1
2
DE-117 Ophthalmic SolutionPhase 31 trial
DE-117 Ophthalmic SolutionPhase 31 trial
DE-117Phase 1/21 trial
Active Trials
NCT01654484Completed60Est. Nov 2012
NCT03691649Completed426Est. Sep 2020
NCT03691662Completed417Est. Oct 2019

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
SantenDE-117 Ophthalmic Solution
SantenDE-117 Ophthalmic Solution
SantenDE-117

Clinical Trials (3)

Total enrollment: 903 patients across 3 trials

NCT03691662SantenDE-117 Ophthalmic Solution

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 4 Study

Start: Sep 2018Est. completion: Oct 2019417 patients
Phase 3Completed
NCT03691649SantenDE-117 Ophthalmic Solution

A Phase III Study Assessing the Efficacy and Safety of DE-117 Ophthalmic Solution Compared With Timolol Maleate Ophthalmic Solution 0.5% in Subjects With Glaucoma or Ocular Hypertension - Spectrum 3 Study

Start: Sep 2018Est. completion: Sep 2020426 patients
Phase 3Completed
NCT01654484SantenDE-117

A Study Assessing the Safety and Efficacy of DE-117 Ophthalmic Solution in Patients With POAG or OHT

Start: Jul 2012Est. completion: Nov 201260 patients
Phase 1/2Completed

Related Jobs in Cardiovascular

Embedded Software and System Test Engineer (H/F)

Cardiawave
Levallois-Perret, France (Hybrid)
Just now

Territory Sales Manager - Iowa / Nebraska

HeartFlow
Cedar Rapids, IA; Des Moines, IA; Omaha, NE; Lincoln, NE
Yesterday
From $150K/yr

Associate Regulatory Affairs Specialist

Medtronic
Mounds View, Minnesota, United States of America
Yesterday
$60K - $90K/yr

Business Development Manager, Post Transplant, Cardio Thoracic

Thermo Fisher Scientific
Remote
Yesterday

Director, Medical Affairs

Abbott
Germany - Hesse - Eschborn
Yesterday

Therapy Development Manager

Abbott
Australia > Doncaster : 666 Doncaster Road
Yesterday

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
1 companies competing in this space

Related Indications

Heart Failure(334)Hypertension(333)Coronary Artery Disease(295)Atrial Fibrillation(288)Pulmonary Arterial Hypertension(103)Acute Coronary Syndrome(62)Pulmonary Hypertension(55)Essential Hypertension(32)Coronary Heart Disease(28)Aortic Valve Stenosis(27)